Can cost studies improve the performance of donor-financed HIV treatment?

AIDS

Volumn 25, Issue 14, 2011, Pages 1795-1796

  Walker, Damian G ^a   Over, Mead ^b   Bertozzi, Stefano M ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

^b CENTER FOR GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; COST CONTROL; DISEASE SEVERITY; DRUG COST; EDITORIAL; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; MALE;

EID: 80052420264     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834a1f77     Document Type: Editorial

References (6)

1. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, Blandford JM. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 2011; 25:000-000.
2. McPake B, Asiimwe D, Mwesigye F, Ofumbi M, Ortenblad L, Streefland P, Turinde A. Informal economic activities of public health workers in Uganda: implications for quality and accessibility of care. Soc Sci Med 1999; 49:849-865. (Pubitemid 29354396)
3. Chaudhury N, Hammer J, Kremer M, Muralidharan K, Rogers FH. Missing in action: teacher and health worker absence in developing countries. J Econ Perspect 2006; 20:91-116. (Pubitemid 43572693)
4. Leonard KL. The cost of imperfect agency in healthcare: evidence from rural Cameroun. J Dev Econ 2009; 88:282-291.
5. Holmes CB, Coggin W, Jamieson D, Mihm H, Granich R, Savio P, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 2010; 304:313-320.
6. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized noninferiority trial. Lancet 2010; 375:123-131